Floatz logo

Tegsedi

FAP

Ionis Pharmaceuticals, Inc.Phase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the FAP cohort.

Asset / SponsorPhaseRating
Eicosapentanoic Acid
S.L.A. Pharma AG
Phase 2/3B
Eloxatin
Parabilis Medicines, Inc.
Phase 1/2CCC
Irinotecan
Parabilis Medicines, Inc.
Phase 1/2CCC
FLUOROURACILUM
Parabilis Medicines, Inc.
Phase 1/2CCC
Nivolumab
Parabilis Medicines, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Tegsedi is also rated in:

familial amyloid neuropathyDormant
BB
Indicative ·
70 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
pregnancy disorderDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →